AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Planning Underway for Phase 3 Development of Tezepelumab in COPD. THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today …
Planning Underway for Phase 3 Development of Tezepelumab in COPD. THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today …